Mast Cell Stabilizers: Cromolyn, Ketotifen, and Quercetin Compared

Mast cell stabilizers are medications and supplements that reduce the tendency of mast cells to degranulate — to release their stored mediators (histamine, tryptase, prostaglandins, leukotrienes) in response to triggers. They are a cornerstone of mast cell activation syndrome (MCAS) treatment, used alongside antihistamines to reduce both acute reactions and chronic baseline inflammation.

Three mast cell stabilizers are most commonly used in MCAS management: cromolyn sodium (a prescription medication), ketotifen (a prescription medication in the US, over-the-counter in many other countries), and quercetin (a natural flavonoid available as a supplement). Each has a different mechanism, different pharmacokinetics, and different clinical applications. Understanding the differences helps patients and physicians choose the right agent — or combination of agents — for each patient's specific symptom profile.

Cromolyn Sodium

Mechanism

Cromolyn sodium (also known as sodium cromoglicate) stabilizes mast cells by blocking calcium channels in the mast cell membrane. Calcium influx is required for mast cell degranulation; by blocking this influx, cromolyn prevents the release of preformed mediators (histamine, tryptase) and the synthesis of newly formed mediators (prostaglandins, leukotrienes). It also inhibits the activation of eosinophils and other immune cells involved in allergic inflammation.

Critically, cromolyn is poorly absorbed from the gastrointestinal tract — less than 1% of an oral dose reaches the systemic circulation. This means that oral cromolyn acts almost exclusively in the gut lumen and gut wall, making it highly effective for GI symptoms but less useful for systemic MCAS manifestations.

Forms and Dosing

Cromolyn is available in several forms:

• Oral solution (Gastrocrom): The primary form used for MCAS. Typically dosed at 100–200 mg four times daily, taken 30 minutes before meals and at bedtime. Some patients require higher doses (up to 400 mg four times daily).
• Inhaled (Intal): Used for asthma and allergic airway disease. Relevant for MCAS patients with significant respiratory symptoms.
• Nasal spray (NasalCrom): Used for allergic rhinitis. Available over-the-counter in the US.
• Eye drops (Opticrom): Used for allergic conjunctivitis.

What Cromolyn Treats Best

Oral cromolyn is most effective for MCAS-related gastrointestinal symptoms: abdominal pain, nausea, vomiting, diarrhea, and bloating. Because it acts locally in the gut, it can dramatically reduce gut mast cell activation without significant systemic effects. Many patients who have failed standard IBS treatments see significant improvement with oral cromolyn.

Inhaled cromolyn is effective for MCAS-related respiratory symptoms (wheezing, coughing, shortness of breath triggered by mast cell activation).

Limitations

The poor GI absorption of oral cromolyn means it has minimal effect on systemic MCAS manifestations — skin symptoms (urticaria, flushing), cardiovascular symptoms (tachycardia, hypotension), neurological symptoms (brain fog, headache), and musculoskeletal symptoms are not well-addressed by oral cromolyn alone.

Cromolyn must be taken consistently — it is a preventive medication, not a rescue medication. It typically takes 2–4 weeks of consistent use to see full benefit. It is not effective for acute reactions.

Gastrocrom is expensive in the US (often $300–500/month without insurance) and may not be covered by all insurance plans. Compounded cromolyn is available from compounding pharmacies at lower cost.

Ketotifen

Mechanism

Ketotifen has a dual mechanism: it is both a mast cell stabilizer and an H1 antihistamine. As a mast cell stabilizer, it blocks calcium channels (similar to cromolyn) and also inhibits the release of mast cell mediators through additional pathways. As an H1 antihistamine, it blocks histamine receptors, preventing histamine from binding to its target tissues.

Unlike cromolyn, ketotifen is well-absorbed systemically, making it effective for both gut and systemic MCAS manifestations.

Forms and Dosing

Ketotifen is available as:

• Oral tablets/capsules: The primary form for systemic MCAS. Typically dosed at 1–2 mg twice daily. Starting at 0.5–1 mg at bedtime and gradually increasing over 2–4 weeks reduces the sedation that many patients experience initially.
• Eye drops (Zaditor, Alaway): Available over-the-counter in the US for allergic conjunctivitis. Not useful for systemic MCAS.

In the United States, oral ketotifen is not FDA-approved and must be obtained from a compounding pharmacy with a prescription. In Canada, Europe, and many other countries, it is available as a standard prescription or over-the-counter medication.

What Ketotifen Treats Best

Ketotifen is the most versatile mast cell stabilizer for systemic MCAS. Its dual action (mast cell stabilization + H1 antihistamine) makes it effective for:

• Skin symptoms (urticaria, flushing, itching, angioedema)
• Gastrointestinal symptoms (though oral cromolyn may be more effective for severe GI disease)
• Cardiovascular symptoms (tachycardia, flushing, hypotension)
• Respiratory symptoms
• Neurological symptoms (some patients report improvement in brain fog and anxiety)

Many MCAS patients who do not achieve adequate control with antihistamines alone see significant improvement when ketotifen is added.

Limitations

Sedation is the primary side effect and the main reason patients discontinue ketotifen. The sedation is most pronounced in the first 2–4 weeks and typically diminishes with continued use. Starting at a low dose (0.5 mg at bedtime) and increasing slowly helps minimize this effect. Some patients find the sedation beneficial if they have significant sleep disruption from MCAS.

Weight gain is reported by some patients on ketotifen, possibly related to its antihistamine effects (H1 blockade can increase appetite).

Availability and cost: The need for compounding in the US adds cost and complexity. Compounded ketotifen typically costs $30–80/month.

Quercetin

Mechanism

Quercetin is a flavonoid found in many plants (onions, apples, berries, capers) that has demonstrated mast cell-stabilizing properties in laboratory studies. It inhibits mast cell degranulation by blocking the signaling pathways that lead to calcium influx and mediator release. It also has anti-inflammatory properties through inhibition of NF-κB (a key inflammatory transcription factor) and antioxidant effects.

Quercetin is not a pharmaceutical drug — it is a dietary supplement. The evidence base is primarily from in vitro (cell culture) and animal studies, with limited clinical trial data in humans. However, many MCAS patients and physicians report significant clinical benefit.

Forms and Dosing

Quercetin is available as a dietary supplement in capsule or powder form. Standard doses used for MCAS range from 500 mg to 1000 mg two to three times daily, taken with meals.

Bioavailability is a significant issue with quercetin — plain quercetin is poorly absorbed from the gut. Several formulations improve bioavailability:

• Quercetin phytosome (quercetin complexed with phosphatidylcholine): significantly improved absorption
• Quercetin with bromelain: bromelain (a pineapple enzyme) may enhance quercetin absorption and has its own anti-inflammatory properties
• Liposomal quercetin: encapsulated in liposomes for improved absorption

What Quercetin Treats Best

Quercetin is most useful as an adjunct to pharmaceutical mast cell stabilizers, particularly for patients who cannot access or tolerate cromolyn or ketotifen. It may be particularly helpful for:

• Mild to moderate MCAS where pharmaceutical stabilizers are not yet warranted
• Patients who prefer to minimize pharmaceutical medications
• As a complement to antihistamines and pharmaceutical stabilizers in patients with moderate to severe MCAS

Some patients report that quercetin helps particularly with histamine-related symptoms (flushing, itching, GI symptoms) and with the neurological symptoms of MCAS.

Limitations

The evidence base for quercetin in MCAS is weaker than for cromolyn or ketotifen. Clinical trials in humans are limited. The supplement industry is also less regulated than pharmaceuticals, so product quality varies significantly between brands.

Quercetin can interact with some medications, including cyclosporine, certain antibiotics, and blood thinners. Patients on multiple medications should check for interactions before starting quercetin.

Choosing Between Them

Most MCAS specialists use a combination approach: oral cromolyn for GI symptoms plus ketotifen for systemic symptoms, with quercetin as an optional adjunct. Antihistamines (H1 and H2) are typically used alongside mast cell stabilizers rather than instead of them.

The choice of which stabilizer to start with depends on the patient's dominant symptoms, access to compounding pharmacies, insurance coverage, and tolerance of side effects. Working with an MCAS-knowledgeable physician to titrate the combination is the most effective approach.